HRP20200477T1 - Kimerni protein sastavljen od domene antagonista ngf i domene antagonista tnfa - Google Patents
Kimerni protein sastavljen od domene antagonista ngf i domene antagonista tnfa Download PDFInfo
- Publication number
- HRP20200477T1 HRP20200477T1 HRP20200477TT HRP20200477T HRP20200477T1 HR P20200477 T1 HRP20200477 T1 HR P20200477T1 HR P20200477T T HRP20200477T T HR P20200477TT HR P20200477 T HRP20200477 T HR P20200477T HR P20200477 T1 HRP20200477 T1 HR P20200477T1
- Authority
- HR
- Croatia
- Prior art keywords
- binding molecule
- seq
- amino acid
- acid sequence
- domain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934828P | 2014-02-02 | 2014-02-02 | |
| EP15701985.2A EP3099713B1 (en) | 2014-02-02 | 2015-02-02 | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
| PCT/EP2015/052098 WO2015114150A1 (en) | 2014-02-02 | 2015-02-02 | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200477T1 true HRP20200477T1 (hr) | 2020-06-26 |
Family
ID=52440681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200477TT HRP20200477T1 (hr) | 2014-02-02 | 2015-02-02 | Kimerni protein sastavljen od domene antagonista ngf i domene antagonista tnfa |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9884911B2 (enExample) |
| EP (2) | EP3696193A1 (enExample) |
| JP (4) | JP6687526B2 (enExample) |
| KR (1) | KR102489452B1 (enExample) |
| CN (2) | CN106459190A (enExample) |
| AU (3) | AU2015212787B2 (enExample) |
| CA (1) | CA2938066C (enExample) |
| CY (1) | CY1123248T1 (enExample) |
| DK (1) | DK3099713T3 (enExample) |
| ES (1) | ES2784238T3 (enExample) |
| HR (1) | HRP20200477T1 (enExample) |
| HU (1) | HUE048478T2 (enExample) |
| LT (1) | LT3099713T (enExample) |
| MX (1) | MX382763B (enExample) |
| PL (1) | PL3099713T3 (enExample) |
| PT (1) | PT3099713T (enExample) |
| RS (1) | RS60156B1 (enExample) |
| RU (1) | RU2678810C2 (enExample) |
| SI (1) | SI3099713T1 (enExample) |
| SM (1) | SMT202000182T1 (enExample) |
| WO (1) | WO2015114150A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102489452B1 (ko) | 2014-02-02 | 2023-01-16 | 메디뮨 리미티드 | Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질 |
| US9862760B2 (en) * | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| US11572395B2 (en) | 2017-09-21 | 2023-02-07 | Merck Patent Gmbh | Fusion protein comprising an FGF-18 moiety |
| WO2021142573A1 (zh) * | 2020-01-13 | 2021-07-22 | 丁邦 | 一种融合蛋白及其制法和用途 |
| US20240026036A1 (en) * | 2020-09-28 | 2024-01-25 | Medimmune Limited | Compounds and methods for treating pain |
| CN114574444B (zh) * | 2020-12-01 | 2024-05-03 | 达达生物技术(北京)有限公司 | 自体纤维母细胞在制备抗类风湿关节炎药物中的应用 |
| TWI821881B (zh) * | 2021-01-29 | 2023-11-11 | 醫研生物科技有限公司 | 腫瘤壞死因子α重組抗體及其用途 |
| CN116179667A (zh) * | 2022-09-21 | 2023-05-30 | 福建中妆技术研究有限公司 | 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7026446B1 (en) * | 1997-12-24 | 2006-04-11 | Diatech Pty Ltd. | Bifunctional molecules |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| DE19926068C1 (de) * | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| NZ529612A (en) | 2001-05-30 | 2006-03-31 | Genentech Inc | Anti-NGF antibodies for the treatment of various disorders |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| PT1556083E (pt) | 2002-10-08 | 2011-03-17 | Rinat Neuroscience Corp | Métodos para tratar a dor pós-cirúrgica pela administração de um anticorpo contra o factor de crescimento nervoso e composições que contêm o mesmo |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| US20080312425A1 (en) | 2004-08-30 | 2008-12-18 | Lonza Biologics Plc. | Ion Exchange Chromatography and Purification of Antibodies |
| PT1846451E (pt) | 2005-01-24 | 2013-08-28 | Elan Pharma Int Ltd | Membros de ligação específica para ngf |
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| CN101802197A (zh) * | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法 |
| US8093364B2 (en) | 2008-01-18 | 2012-01-10 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| MX2010014574A (es) * | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| JP2011016676A (ja) * | 2009-07-07 | 2011-01-27 | Sumitomo Electric Ind Ltd | 窒化物半導体基板の製造方法 |
| BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| JP2013512674A (ja) * | 2009-12-02 | 2013-04-18 | アクセルロン ファーマ， インコーポレイテッド | Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法 |
| SG184473A1 (en) * | 2010-04-07 | 2012-11-29 | Abbvie Inc | Tnf-alpha binding proteins |
| DK2714738T3 (en) * | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| AU2012336069A1 (en) | 2011-11-07 | 2014-05-22 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| WO2013101972A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2014106001A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
| BR112015023557A2 (pt) | 2013-03-15 | 2017-10-24 | Abbvie Inc | proteínas de ligações dual específicas direcionadas contra tnfa |
| KR102489452B1 (ko) * | 2014-02-02 | 2023-01-16 | 메디뮨 리미티드 | Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US20210009671A1 (en) | 2019-05-10 | 2021-01-14 | Medimmune Limited | Compounds and methods for treating pain |
-
2015
- 2015-02-02 KR KR1020167023831A patent/KR102489452B1/ko active Active
- 2015-02-02 HR HRP20200477TT patent/HRP20200477T1/hr unknown
- 2015-02-02 LT LTEP15701985.2T patent/LT3099713T/lt unknown
- 2015-02-02 HU HUE15701985A patent/HUE048478T2/hu unknown
- 2015-02-02 EP EP19214210.7A patent/EP3696193A1/en active Pending
- 2015-02-02 JP JP2016549449A patent/JP6687526B2/ja active Active
- 2015-02-02 AU AU2015212787A patent/AU2015212787B2/en active Active
- 2015-02-02 DK DK15701985.2T patent/DK3099713T3/da active
- 2015-02-02 CA CA2938066A patent/CA2938066C/en active Active
- 2015-02-02 ES ES15701985T patent/ES2784238T3/es active Active
- 2015-02-02 RU RU2016132370A patent/RU2678810C2/ru active
- 2015-02-02 SI SI201531149T patent/SI3099713T1/sl unknown
- 2015-02-02 PT PT157019852T patent/PT3099713T/pt unknown
- 2015-02-02 WO PCT/EP2015/052098 patent/WO2015114150A1/en not_active Ceased
- 2015-02-02 CN CN201580017113.5A patent/CN106459190A/zh active Pending
- 2015-02-02 US US14/612,137 patent/US9884911B2/en active Active
- 2015-02-02 CN CN202311359790.8A patent/CN118085103A/zh active Pending
- 2015-02-02 EP EP15701985.2A patent/EP3099713B1/en active Active
- 2015-02-02 SM SM20200182T patent/SMT202000182T1/it unknown
- 2015-02-02 PL PL15701985T patent/PL3099713T3/pl unknown
- 2015-02-02 MX MX2016010030A patent/MX382763B/es unknown
- 2015-02-02 RS RS20200396A patent/RS60156B1/sr unknown
-
2017
- 2017-12-21 US US15/849,771 patent/US10457728B2/en active Active
-
2019
- 2019-09-17 US US16/573,192 patent/US11053307B2/en active Active
-
2020
- 2020-04-01 JP JP2020065513A patent/JP7074792B2/ja active Active
- 2020-04-10 CY CY20201100338T patent/CY1123248T1/el unknown
- 2020-09-11 AU AU2020230316A patent/AU2020230316B2/en active Active
-
2021
- 2021-05-28 US US17/333,291 patent/US11897949B2/en active Active
-
2022
- 2022-05-11 JP JP2022077858A patent/JP7520070B2/ja active Active
-
2023
- 2023-12-21 AU AU2023285832A patent/AU2023285832A1/en active Pending
-
2024
- 2024-01-03 US US18/403,043 patent/US20240262902A1/en active Pending
- 2024-07-08 JP JP2024109298A patent/JP2024133644A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200477T1 (hr) | Kimerni protein sastavljen od domene antagonista ngf i domene antagonista tnfa | |
| HRP20231118T1 (hr) | Sintetizirani polipeptidi koji vežu transferinske receptore | |
| PH12018502414A1 (en) | Dual transit peptides for targeting polypeptides | |
| HRP20201392T1 (hr) | Fgf21 fuzijski proteini dugotrajnog djelovanja i farmaceutski pripravci koji sadrže iste | |
| JP7536294B2 (ja) | 抗体のＦｃ領域改変体 | |
| JP2012025737A5 (enExample) | ||
| JP2012025766A5 (enExample) | ||
| HRP20241775T1 (hr) | Bispecifična protutijela koja se specifično vežu na pd1 i lag3 | |
| HRP20191766T1 (hr) | Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene | |
| PE20211055A1 (es) | Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas | |
| RU2016139006A (ru) | Мультимерные fc-белки | |
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| RU2015142999A (ru) | Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения | |
| CN106573986A (zh) | 多特异性抗体 | |
| ME03709B (me) | Fuzijski proteini | |
| RU2018138703A (ru) | Слитые полипептиды cd40l-fc и способы их применения | |
| HRP20231382T1 (hr) | Pd-l1 varijanta imunomodulacijskih proteina i njihova upotreba | |
| MX2023005420A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| HRP20210635T1 (hr) | Novi mutant humanog seruma albumina | |
| CA2902505A1 (en) | Anti-c-met tandem fc bispecific antibodies | |
| HRP20202024T1 (hr) | Cd3-vežuća domena | |
| JP2017512063A5 (enExample) | ||
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| AU2014247175A1 (en) | Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use | |
| RU2015101699A (ru) | Слитые полипептиды и конъюгаты полипептида лиганда рецептора инкретина и fc-области с измененной fc-эффекторной функцией |